Medtronic’s Stanton Stresses The Downsides Of Cost-Effectiveness Analyses
This article was originally published in The Gray Sheet
Executive Summary
Cost-effectiveness analysis should not be included in Medicare coverage because the methodology is "too immature" and lacks a universal threshold for how much a quality life-year is worth, according to Medtronic Medical Director Marshall Stanton, MD
You may also be interested in...
ICD Coverage Saga Reaches Dénouement With SCD-HeFT Study Publication
CMS says it likely will issue a final ICD coverage decision Jan. 26, with the publication of Medtronic's SCD-HeFT study in the New England Journal of Medicine.
ICD Coverage Saga Reaches Dénouement With SCD-HeFT Study Publication
CMS says it likely will issue a final ICD coverage decision Jan. 26, with the publication of Medtronic's SCD-HeFT study in the New England Journal of Medicine.
Tunis Praises NEJM Editorial Calling On Doctors To Care About Societal Costs
Physicians should take more responsibility for demonstrating cost-effectiveness of expensive therapies such as implantable cardioverter defibrillators, according to an editorial in the Dec. 9 issue of the New England Journal of Medicine